Johnson & Johnson clears a key OTTAVA hurdle, but the harder robotics test comes next

Robotic surgery is opening up. Johnson & Johnson’s OTTAVA data may test whether hospitals want a new soft tissue platform.

Robotic surgery is opening up. Johnson & Johnson’s OTTAVA data may test whether hospitals want a new soft tissue platform.
Read how Johnson & Johnson’s ETHICON 4000 CE Mark approval could reshape surgical stapling, hospital economics, and future robotic integration.

EndoQuest wins FDA approval to complete PARADIGM Trial for its ELS system. Find out what this milestone means for robotic GI surgery innovation.

Vicarious Surgical shifts software development to a global partner to cut costs and hit clinical trial milestones. Here’s what this means for its platform.